CHINOOK THERAP. DL-,0001 (290A.BE)
- GlobeNewswire
Chinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2023 at 11:15 am EST, and participate in 1x1 meetings. To access the audio webcast and subsequent archived recording of this and
- GlobeNewswire
Chinook Therapeutics to Present at Upcoming Investor Conferences
SEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in fireside chats and one-on-one meetings at the following upcoming investor conferences: 5th Annual Evercore ISI HealthCONx Conference – Fireside chat on Tuesday, November 29th at 10:30 am ESTPiper Sandler 34th An
- GlobeNewswire
Chinook Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
SEATTLE, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the quarter and nine months ended September 30, 2022. “During the third quarter of 2022, we continued advancing our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases. We are ple
